Bank Julius Baer & Co. Ltd Zurich Cuts Position in DexCom, Inc. (NASDAQ:DXCM)

Bank Julius Baer & Co. Ltd Zurich lessened its holdings in DexCom, Inc. (NASDAQ:DXCM) by 3.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 46,169 shares of the medical device company’s stock after selling 1,485 shares during the period. Bank Julius Baer & Co. Ltd Zurich’s holdings in DexCom were worth $5,729,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Sands Capital Management LLC boosted its holdings in DexCom by 4.3% in the 3rd quarter. Sands Capital Management LLC now owns 13,660,670 shares of the medical device company’s stock worth $1,274,541,000 after buying an additional 557,543 shares during the last quarter. Blair William & Co. IL boosted its holdings in DexCom by 1.7% in the 3rd quarter. Blair William & Co. IL now owns 4,507,153 shares of the medical device company’s stock worth $420,517,000 after buying an additional 73,654 shares during the last quarter. Northern Trust Corp boosted its holdings in shares of DexCom by 2.4% during the 3rd quarter. Northern Trust Corp now owns 3,896,515 shares of the medical device company’s stock worth $363,545,000 after purchasing an additional 91,249 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of DexCom by 1.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,160,961 shares of the medical device company’s stock worth $201,618,000 after purchasing an additional 28,621 shares during the last quarter. Finally, Winslow Capital Management LLC acquired a new position in shares of DexCom during the 3rd quarter worth approximately $173,120,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Insider Buying and Selling at DexCom

In other DexCom news, CFO Jereme M. Sylvain sold 3,363 shares of the business’s stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $116.73, for a total value of $392,562.99. Following the sale, the chief financial officer now owns 71,142 shares of the company’s stock, valued at $8,304,405.66. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, CFO Jereme M. Sylvain sold 3,363 shares of the company’s stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $116.73, for a total transaction of $392,562.99. Following the sale, the chief financial officer now owns 71,142 shares of the company’s stock, valued at $8,304,405.66. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Matthew Vincent Dolan sold 1,990 shares of the company’s stock in a transaction on Monday, April 15th. The stock was sold at an average price of $137.81, for a total value of $274,241.90. Following the sale, the executive vice president now directly owns 42,377 shares in the company, valued at approximately $5,839,974.37. The disclosure for this sale can be found here. Insiders have sold a total of 189,375 shares of company stock valued at $25,530,859 over the last quarter. 0.41% of the stock is owned by company insiders.

DexCom Stock Down 9.9 %

Shares of NASDAQ DXCM opened at $124.34 on Friday. The firm has a market cap of $49.24 billion, a price-to-earnings ratio of 80.22, a PEG ratio of 2.37 and a beta of 1.20. The company has a quick ratio of 2.48, a current ratio of 2.84 and a debt-to-equity ratio of 1.18. DexCom, Inc. has a 52-week low of $74.75 and a 52-week high of $142.00. The business’s 50 day moving average is $131.13 and its two-hundred day moving average is $118.30.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, April 25th. The medical device company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. The company had revenue of $921.00 million for the quarter, compared to analyst estimates of $911.20 million. DexCom had a return on equity of 31.38% and a net margin of 16.82%. Research analysts predict that DexCom, Inc. will post 1.76 EPS for the current year.

Analyst Ratings Changes

DXCM has been the topic of several recent research reports. Citigroup boosted their target price on DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a report on Wednesday, April 3rd. Royal Bank of Canada initiated coverage on DexCom in a report on Tuesday, March 12th. They set an “outperform” rating and a $165.00 target price on the stock. Raymond James boosted their target price on DexCom from $151.00 to $160.00 and gave the stock a “strong-buy” rating in a report on Friday. UBS Group boosted their target price on DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a report on Wednesday, April 10th. Finally, Canaccord Genuity Group boosted their target price on DexCom from $144.00 to $145.00 and gave the stock a “buy” rating in a report on Friday. Three equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, DexCom has an average rating of “Moderate Buy” and an average price target of $141.67.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.